Company intelligence / Profile preview
TOT Biopharm
Suzhou, Jiangsu, Chinatotbiopharm.com ↗
- Ownership
- Private
- Employees
- ~611
- Development stage
- Other
01
Overview
TOT Biopharm has developed a robust pipeline of oncology drug candidates including monoclonal antibodies and antibody-drug conjugates. The company has achieved commercial production of listed products such as a bevacizumab biosimilar approved in Nigeria. It operates both as a developer of proprietary drugs and as a CDMO partner for global clients.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyAntibody-drug conjugateBiologic
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Diversified strategic partnerships with domestic and international pharmaceutical companies for CDMO services; specific partners not named publicly
Beyond the preview
Go deeper on TOT Biopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TOT Biopharm.